Recent Updates
Recently added Catalysts

MK0364

Phase 2

Obesity | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: Sep 9, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment500
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00109148An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)PHASE2 COMPLETED 500Jul 1, 2004Feb 1, 2005Sep 9, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0364DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients who are obese (considerably overweight) based on body mass index. Exclusion Criteria: * Patients with serious or unstable current or past medical conditions

Unlock Eligibility Criteria